Future of the Prevention and Treatment of Coronary Artery Disease-Reference-Cited by-同舟云学术

Future of the Prevention and Treatment of Coronary Artery Disease

Published:2016 Issue:5 Volume:80 Page:1067-1072
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Steg Philippe Gabriel¹²,Ducrocq Grégory¹

Affiliation:

1. French Alliance for Cardiovascular clinical Trials (FACT), and Université Paris-Diderot, INSERM U-1148, Bichat Hospital, Fibrosis, Inflammation and Remodeling (FIRE) Department, Assistance Publique-Hôpitaux de Paris

2. National Heart and Lung Institute, Institute of Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/80/5/80_CJ-16-0266/_pdf

Reference33 articles.

1. 1. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations: Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547–1557.

2. 2. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 2007; 356: 2388–2983.

3. 3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG): European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635–1701.

4. 4. Task Force Members;Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949–3003.

5. 5. Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: Post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 2014; 7: 872–881.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vascular medicine in the 21^st century: Embracing comprehensive vasculature evaluation and multidisciplinary treatment;World Journal of Clinical Cases;2024-09-26

2. Circulating Levels of Calprotectin as a Biomarker in Patients With Coronary Artery Disease: A Systematic Review and Meta‐Analysis;Clinical Cardiology;2024-07

3. Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: A systematic review and meta-analysis;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2024-01

4. Extracellular Vesicles and Cardiovascular Disease: Diagnostic and Therapeutic Perspective;Extracellular Vesicles in Human Health and Diseases;2024

5. Proteolysis Targeting Chimera (PROTACs): An Attractive Technology in CVD Therapeutics—Opportunities and Challenges;PROTAC-Mediated Protein Degradation: A Paradigm Shift in Cancer Therapeutics;2024